Mounjaro® (tirzepatide) is a novel antidiabetic drug that uniquely combines GIP and GLP-1 receptor agonism to improve both blood sugar control and weight loss in patients with Type 2 Diabetes. Approved in 2022 by both FDA and EMA, it offers greater efficacy than traditional GLP-1 receptor agonists. The SURPASS-4 trial not only confirmed its metabolic benefits but also noted reduced mortality compared to insulin. Its dual-action mechanism positions tirzepatide as a promising therapy for complex metabolic conditions.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Hemi Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
